By Adriano Marchese
Knight Therapeutics Inc. said Tuesday that it has received approval from Health Canada for its drug neratinib for the treatment of patients with HER2-overexpressed or amplified breast cancer.
The Canadian specialty pharmaceutical company said the approval for the treatment, also known as Nerlynx, is based on the results of the global phase-three NALA trial.
The company noted that women with breast cancer that over-expresses HER2--which represents around 20% of breast cancer tumors--are at greater risk for disease progression and death.
"We are pleased to provide Canadian HER2-positive breast cancer patients and physicians with an effective medicine following previous treatment with other anti-HER2 agents in the metastatic setting," Country Manager Canada Jody Engel said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
07-06-21 0904ET